The collaboration aims to streamline iPSC manufacturing by combining automation with standardized reagents for reproducible, scalable cell therapy processes.
Axol Bioscience’s updated iPSC library will hopefully provide researchers with diverse patient-derived cell lines and tools for advanced ophthalmology studies.
The partnership aims to deliver standardized tools for stem cell and organoid research, addressing reproducibility and scalability challenges.
Startups in regenerative medicine gain free lab access, advanced equipment, and support to accelerate product development and commercialization.
NurExone secures U.S. patent protection for its exosome production method, supporting scale-up and clinical supply chain readiness.
Sumitomo Pharma and RACTHERA seek approval for a novel iPS cell-based therapy targeting motor symptoms in advanced Parkinson’s.
The Australian biotech company is preparing for trials and commercialization of its stem cell therapy platform for Crohn's disease, StemSmart.
Dr. Koji Tanabe discusses IPS cell advancements, mass manufacturing, and their future in medicine.
The Japanese Society for Regenerative Medicine and imec will jointly pursue nanobiotechnology for regen med applications.
The acquisition is expected to help expand its cell therapy capabilities, gaining advanced microfluidic cell sorting tech for enhanced research
